Dräger's 4.6% Margin Is a Customs Refund Wearing a Turnaround's Clothes

The margin that isn't

On the surface, Drägerwerk's first nine months of 2026 look like an inflection. EBIT rose by roughly EUR 35 million to about EUR 112 million, lifting the margin from 3.3% to 4.6%. Free cash flow went from about EUR 16 million to roughly EUR 114 million. Net financial debt fell by around EUR 116 million to about EUR 106 million, or 0.3x EBITDA, and return on capital employed jumped from 12.0% to 15.6%. Those are real numbers, and the cash is real.

But EUR 27.9 million of that EBIT is a tariff refund — EUR 7.8 million booked in Q2 and EUR 20.1 million in Q3 — and EUR 3.8 million of it relates to current-year customs expense, so it does nothing year-over-year. Meanwhile Dräger paid EUR 25.8 million of non-refundable U.S. customs duty. The CFO was unusually blunt about the wash:

Strip the refunds out and the nine-month margin is closer to the mid-3% area, with an underlying improvement of about EUR 11 million — respectable, not transformative. The quarter itself was worse than the year: Q3 EBIT fell from roughly EUR 57 million to EUR 48 million, margin 6.8% to 5.6%, on net sales growth of just 1%. Functional cost is now the single loudest theme in this transcript, with freight costs, one-off share-price-linked management accruals and the Lübeck distribution-centre handover all stacking on top of the collective bargaining step-up.

Worth noting the refund was not a Dräger insight. It was a market-wide wave: net tariff refunds and tariff refund were among the hottest global keywords of the second and third quarters, with dozens of U.S.-exposed industrial and consumer names booking IEEPA recoveries. Dräger is a late, small participant riding a theme everyone already knows.

And it was pre-flagged. In March the CFO was explicit that it wasn't in the plan:

The upside arrived — and landed almost exactly offset by duty paid. The shape of the tariff story has flipped from optionality to arithmetic.

Seven years, one sentence

The genuinely new fact in this call barely got a paragraph. The FDA warning letter that has shadowed Dräger's monitoring business — a fixture of the 2025 transcripts, where warning letter ranked near the top of the keyword table — has been lifted.

For the warning letter, that after almost 7 years is now lifted. And so we are prepared to reap the benefits from the approvals of the products and from no longer employing resources on all the work that's associated with satisfying the FDA to fulfill all the requirements. So that's done. What it means for the future, stay tuned for our Capital Markets Day.

Analyst Harald Hof asked directly what it means for 2027 and beyond, and got deferred to 18 November. That deferral is the tension of the whole call. The regulatory overhang on the higher-multiple division is gone — and management will not put a number on it, which either means the number is being saved for a Capital Markets Day reveal or the number is small.

The Medical division still lost EUR 9.7 million at the EBIT line over nine months, a margin of -0.7%. Oliver Reinberg made the sharpest observation of the session — that excluding the refund, the medical margin was actually down year-over-year — and the CFO's answer wandered into"higher efficiency in research" before being cut off and redirected. Q3 Medical EBIT fell from EUR 11 million to EUR 4.5 million. The recovery story is entirely forward-looking.

Safety is the engine, and it just downshifted

Safety remains the profit centre: order intake up 13.1% over nine months and 20% in Q3, with Germany up almost 28% on a single defense sector order — low double-digit millions, delivered over two to three years, so it will not convert to revenue quickly. Nine-month EBIT rose from roughly EUR 100 million to EUR 122 million, margin above 11%. But Q3 EBIT came in about EUR 2 million below prior year and the quarterly margin fell from 12.6% to 11.4%.

That matters because in July the CEO was asked whether Safety margins had peaked. His answer: “I would not say it's the peak.” — Stefan Dräger · 2026-07-30 The very next quarter the number came down, and CFO Gert-Hartwig Lescow warned of an 11.1% functional expense rise in the division. The EUR 100 million-to-EUR 300 million defense ambition by 2028 is unchanged, and the CEO was expansive about the pipeline:

He also volunteered the FDNY tender — a Fire Department of New York account held by Dräger's own U.S. market company, Scott, for seventy years, now out of the process while the parent remains shortlisted. He was careful to call it a bonus, not a plan.

What stopped being said

China has been a chronic disappointment for at least four quarters, and March's framing — "“relatively stable and continues to be on a much lower level than it used to” — Stefan Dräger, CEO · 2026-03-24" — carried through to "below our expectations and no growth." What is new is the competitive read-across. Mindray and Edan are posting double-digit domestic declines, and the CEO's conclusion is that this makes them more dangerous abroad:

Dräger's counter-moves — hiring Mindray's chief salesperson for North America, and a Guangdong provincial government that is reportedly promoting Dräger in local tenders — are genuinely company-unique details that no keyword scan will surface.

Two other things worth flagging. First, the Mexico effect is doing a lot of narrative work: the prior-year EUR-hundreds-of-millions hospital infrastructure order distorts every regional comparison, and Medical order intake would have been "almost stable" without it. Second, the 2027 headwind nobody expected: supply-chain shortages spilling over from the AI buildout. For a component buyer, the data-centre capex boom reads as procurement risk, not opportunity — a refreshingly unhyped framing.

What genuinely improved is the balance sheet. Net debt to EBITDA of 0.3x, an equity ratio near 52%, a confirmed 2-6% sales and 6-8% EBIT margin guide that now requires a very tight Q4 — the CFO conceded roughly a third of Q3's cost increase was one-off and that holding Q4 flat versus Q3 "requires a tighter spending management." The dividend policy of at least 30% of net income is unchanged.

The real event is 18 November in Lübeck, where Ambition 2030 and the Medical margin roadmap land. A Markets Day was itself one of the more prominent global themes this quarter, as peers leaned on capital-markets events to reset narratives. Dräger is doing the same, with one difference: it is deferring the most valuable single data point it now owns.